© AP/CDC/Cynthia S. Goldsmith/Russell RegnerAn electron microscope image shows monkeypox virions obtained from a human skin sample.
The US health authorities have signed a deal for
$119 million in vaccine doses against the monkeypox virus, after
a Massachusetts man was diagnosed with the rare but potentially serious illness earlier this week.
The Biomedical Advanced Research and Development Authority (BARDA) - a government agency devoted to combating pandemics and bioterrorism -
signed the multi-million-dollar contract with Danish pharma firm Bavarian Nordic on Wednesday, the company announced in a
statement.
The $119 million deal is
one in a series of contract options which could ultimately reach a total value of $299 million if exercised, in exchange for around
13 million freeze-dried doses of the Jynneos vaccine. It was originally created for smallpox, but was
approved for use against monkeypox by the Food and Drug Administration (FDA) in 2019, just months before the first cases of Covid-19 were detected in China.
Initial deliveries for the Jynneos shot won't come until 2023, the company said, noting that the full 13 million doses are expected to be ready sometime between 2024 and 2025 should BARDA agree to extend the contract.
Comment: See also: